 previous article in this issue | next article in this issue  |
|
Document Details : Title: Dermatological side effects of current and upcoming targeted therapies in oncology Author(s): BONNY M, BUYSE V, BROCHEZ L Journal: Acta Clinica Belgica Volume: 66 Issue: 2 Date: 2011 Pages: 97-103 DOI: 10.2143/ACB.66.2.1002924 Abstract : Targeted therapies are gaining fi eld in oncology practice. Some of them are already well established, others are upcoming. They target cancer cells more selectively, therefore causing less collateral damage. Dermatologic side eff ects are common and sometimes class specific. The skin toxicity profi le of EGFR inhibitors, MEK en Raf inhibitors, mTOR inhibitors, VEGF targeting molecules, multikinase inhibitors, the HER2 monoclonal antibody trastuzumab and the CTLA-4 monoclonal antibodies are discussed. When possible, a pathogenic mechanism and treatment options are described. |
